CIK 0001800315 · Non-accelerated filer<br>Smaller reporting company
Damora Therapeutics, Inc.
Sign in to watch- Ticker
- DMRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 371957007
- Phone
- (781) 281-9020
- Business address
- 100 FIFTH AVENUE, SUITE 700, WALTHAM, MA, 02451
- Former names
- Galecto, Inc., Galecto Inc.
- Open-market buys, last 90 days
- $252,875
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$252,875. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-11-02 | Khuong Chau Quang Director | Purchase | +523,833 | $15.00 | $7.9M | 2,579,657 |
| 2020-11-02 | Khuong Chau Quang Director | Purchase | +209,500 | $15.00 | $3.1M | 1,031,811 |
| 2020-11-02 | Khuong Chau Quang Director | Conversion · Series C-2 Preferred Stock | −291,999 | 0 | ||
| 2020-11-02 | Khuong Chau Quang Director | Conversion · Series C-2 Preferred Stock | −116,800 | 0 | ||
| 2020-11-02 | Khuong Chau Quang Director | Conversion · Series C-4 Preferred Stock | −272,533 | 0 | ||
| 2020-11-02 | Khuong Chau Quang Director | Conversion · Series C-4 Preferred Stock | −109,013 | 0 | ||
| 2020-11-02 | Khuong Chau Quang Director | Conversion · Series C-5 Preferred Stock | −77,866 | 0 | ||
| 2020-11-02 | Khuong Chau Quang Director | Conversion · Series C-5 Preferred Stock | −31,147 | 0 | ||
| 2020-11-02 | Khuong Chau Quang Director | Conversion · Series D Preferred Stock | −148,395 | 0 | ||
| 2020-11-02 | Khuong Chau Quang Director | Conversion · Series D Preferred Stock | −59,350 | 0 | ||
| 2020-11-02 | Khuong Chau Quang Director | Conversion · Series D Preferred Stock | −73,773 | 0 | ||
| 2020-11-02 | Christgau Stephan Director | Conversion | +479,470 | 479,470 | ||
| 2020-11-02 | Christgau Stephan Director | Purchase | +66,666 | $15.00 | $1000K | 546,136 |
| 2020-11-02 | Christgau Stephan Director | Conversion · Series D Preferred Stock | −184,433 | 0 | ||
| 2020-10-07 | Pedersen Anders Chief Operating Officer | Grant or award · Stock Option (right to buy) | +77,991 | 77,991 | ||
| 2020-10-07 | Schambye Hans T. Chief Executive Officer | Grant or award · Stock Option (right to buy) | +519,940 | 519,940 | ||
| 2020-09-25 | GOLDFISCHER CARL Director | Grant or award · Series D Preferred Stock | +3,688 | $27.11 | $100K | 3,688 |
| 2020-09-25 | ORBIMED ADVISORS LLC Director | Grant or award · Series D Preferred Stock | −148,395 | $27.11 | $4.0M | 148,395 |
| 2020-09-25 | ORBIMED ADVISORS LLC Director | Grant or award · Series D Preferred Stock | −59,350 | $27.11 | $1.6M | 59,350 |
| 2020-09-25 | ORBIMED ADVISORS LLC Director | Grant or award · Series D Preferred Stock | −73,773 | $27.11 | $2.0M | 73,773 |
Page 11 of 12 · 227 trades